[go: up one dir, main page]

MX2019003938A - Compuestos espirociclicos. - Google Patents

Compuestos espirociclicos.

Info

Publication number
MX2019003938A
MX2019003938A MX2019003938A MX2019003938A MX2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A MX 2019003938 A MX2019003938 A MX 2019003938A
Authority
MX
Mexico
Prior art keywords
spirocyclic compounds
compounds
spirocyclic
ameliorating
treating
Prior art date
Application number
MX2019003938A
Other languages
English (en)
Inventor
Kahraman Mehmet
Qinhua Huang Peter
Duane Bunker Kevin
Original Assignee
Zeno Royalties & Milestones Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalties & Milestones Llc filed Critical Zeno Royalties & Milestones Llc
Publication of MX2019003938A publication Critical patent/MX2019003938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción se describen compuestos espirocíclicos, junto con composiciones farmacéuticas y métodos para mejorar y/o tratar un cáncer descrito en la presente descripción con uno o más de los compuestos descritos en la presente descripción.
MX2019003938A 2016-10-05 2017-10-03 Compuestos espirociclicos. MX2019003938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
MX2019003938A true MX2019003938A (es) 2019-06-10

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003938A MX2019003938A (es) 2016-10-05 2017-10-03 Compuestos espirociclicos.

Country Status (13)

Country Link
US (2) US10934304B2 (es)
EP (1) EP3523306A4 (es)
JP (2) JP6949952B2 (es)
KR (1) KR20190075931A (es)
CN (1) CN109890827A (es)
AU (1) AU2017339890A1 (es)
BR (1) BR112019005305A2 (es)
CA (1) CA3037064A1 (es)
IL (1) IL265752A (es)
MX (1) MX2019003938A (es)
RU (1) RU2019107667A (es)
TW (1) TW201817732A (es)
WO (1) WO2018067512A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
MX393494B (es) 2013-04-19 2025-03-24 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PL3277690T3 (pl) 2015-04-03 2020-08-24 Recurium Ip Holdings, Llc Związki spirocykliczne
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020049017A1 (en) * 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2025096858A1 (en) * 2023-10-31 2025-05-08 C4 Therapeutics, Inc. Compounds for the degradation of mutant braf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1976919A (zh) 2004-05-14 2007-06-06 沃泰克斯药物股份有限公司 作为erk蛋白激酶抑制剂的吡咯化合物、它们的合成和中间体
KR101417136B1 (ko) * 2005-12-13 2014-08-07 머크 샤프 앤드 돔 코포레이션 Ｅｒｋ 억제제인 폴리사이클릭 인다졸 유도체 및 이를 포함하는 약제학적 조성물
US7902363B2 (en) 2006-11-17 2011-03-08 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
WO2008156739A1 (en) * 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
WO2010027567A2 (en) 2008-07-23 2010-03-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
US9687550B2 (en) 2009-12-07 2017-06-27 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
AR095036A1 (es) 2013-03-14 2015-09-16 Kalyra Pharmaceuticals Inc Compuestos analgésicos bicíclicos
JP6322770B2 (ja) 2014-12-22 2018-05-09 イーライ リリー アンド カンパニー Ｅｒｋ阻害剤
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
PL3277690T3 (pl) * 2015-04-03 2020-08-24 Recurium Ip Holdings, Llc Związki spirocykliczne

Also Published As

Publication number Publication date
TW201817732A (zh) 2018-05-16
JP2021193138A (ja) 2021-12-23
EP3523306A1 (en) 2019-08-14
WO2018067512A8 (en) 2018-11-01
RU2019107667A (ru) 2020-11-06
NZ751398A (en) 2021-03-26
US10934304B2 (en) 2021-03-02
KR20190075931A (ko) 2019-07-01
BR112019005305A2 (pt) 2019-07-02
JP6949952B2 (ja) 2021-10-13
WO2018067512A1 (en) 2018-04-12
RU2019107667A3 (es) 2021-01-27
AU2017339890A1 (en) 2019-04-11
US20200207776A1 (en) 2020-07-02
CA3037064A1 (en) 2018-04-12
EP3523306A4 (en) 2020-05-06
US20210115058A1 (en) 2021-04-22
JP2019534261A (ja) 2019-11-28
CN109890827A (zh) 2019-06-14
IL265752A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
MX2019003938A (es) Compuestos espirociclicos.
ZA201807399B (en) Egfr inhibitor compounds
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017501999A1 (en) K-ras modulators
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX379622B (es) Compuestos espirociclicos
MX2018003472A (es) Moduladores de la expresion de kras.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX2019007021A (es) Anticuerpos il-11ra.
SI3580211T1 (sl) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za zdravljenje raka
PH12018502020A1 (en) Methods for treating and preventing c. difficile infection
GB2541571A (en) Pharmaceutical compositions
EP4193993A3 (en) Combinations of cannabinoids and n-acylethanolamines
MX2021009899A (es) Administracion y dosificacion de diaminofenotiazinas.
MX2017014436A (es) Compuestos biciclicos.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
EP4286005A3 (en) Cancer treatment
EP4339192A3 (en) Compounds and compositions for the treatment of cancer
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
WO2016130581A8 (en) Combination cancer therapy
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
EP4541423A3 (en) Dosing regimen of avelumab for the treatment of cancer